SYMQYSymbio Pharmaceuticals Ltd

About Symbio Pharmaceuticals Ltd (SYMQY)

Symbio Pharmaceuticals Ltd (SYMQY) is a Drug Manufacturers - Specialty & Generic company headquartered in Minato-ku, Tokyo, Japan whose shares trade over-the-counter on the Pink tier.

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.

SYMQY key facts

Ticker symbol

SYMQY

Market tier

Pink

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Minato-ku, Tokyo, Japan

Country of incorporation

JP

Reporting standard

International Reporting: Tokyo Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2023)

Symbio Pharmaceuticals Ltd leadership

• Takaaki Fukushima — Officer, CFO
• Makio Yamaguchi — Assistant to the CFO

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · Pink stocks · OTC stocks starting with S